Cytori Therapeutics (CYTX) Misses Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts CYTX Hot Sheet
Join SI Premium – FREE
Cytori Therapeutics (NASDAQ: CYTX) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.38 million versus the consensus estimate of $2.01 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- AAR Corp. (AIR) Tops Q1 EPS by 18c
- CarMax (KMX) Tops Q2 EPS by 43c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
